NASDAQ: GNLX - Genelux Corporation

Lønnsomhet i seks måneder: +45.03%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan Genelux Corporation

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC.

flere detaljer
Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2023-01-26
ISIN US36870H1032
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.genelux.com
Цена ао 5.95
Prisendring per dag: +0.813% (2.46)
Prisendring per uke: +9.25% (2.27)
Prisendring per måned: -7.81% (2.69)
Prisendring over 3 måneder: +14.29% (2.17)
Prisendring over seks måneder: +45.03% (1.71)
Prisendring per år: -82.3% (14.01)
Prisendring over 3 år: 0% (2.48)
Prisendring over 5 år: 0% (2.48)
Prisendring over 10 år: 0% (2.48)
Prisendring siden begynnelsen av året: -7.81% (2.69)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 2158.4 1
P/BV 18.84 1
P/E 0 0
EV/EBITDA -15.55 0
Total: 2.13

Effektivitet

Navn Betydning Karakter
ROA, % -101.45 0
ROE, % -145.31 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.1088 10
Total: 10

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % -98.46 0
Lønnsomhet Ebitda, % 154.39 10
Lønnsomhet EPS, % 135.19 10
Total: 8
Flere detaljer

Institusjoner Volum Dele, %
Blackrock Inc. 1196123 4.48
Vanguard Group Inc 980993 3.67
Geode Capital Management, LLC 386634 1.45
State Street Corporation 231065 0.86
AE Wealth Management LLC 194875 0.73
Northern Trust Corporation 160816 0.6
Provident Wealth Management, LLC 157137 0.59
Charles Schwab Investment Management, Inc. 149604 0.56
Bank Of New York Mellon Corporation 53841 0.2
AMG National Trust Bank 50346 0.19

ETF Dele, % Lønnsomhet for året, % Utbytte, %
Range Cancer Therapeutics ETF 0.53743 47.24 0.11955
iShares Micro-Cap ETF 0.01521 17.09 1.54048
Schwab U.S. Small-Cap ETF 0.0013 17.47 1.51433



Veileder Stillingstittel Betaling Fødselsår
Mr. Thomas Zindrick J.D. Chairman, CEO & President 570.99k 1959 (66 år)
Mr. Sean Ryder J.D. General Counsel & Corporate Secretary 380k 1969 (56 år)
Ms. Lourie S. Zak Chief Financial Officer 346.19k 1963 (62 år)
Dr. Joseph Cappello Ph.D. Chief Technical Officer 213.08k 1957 (68 år)
Dr. Yong Yu Ph.D. Senior Vice President of Clinical Development 242.62k 1971 (54 år)
Prof. Paul Scigalla M.D., Ph.D. Chief Medical Officer N/A 1945 (80 år)
Mr. Ralph Smalling B.Sc. VP & Head of Regulatory Affairs N/A 1957 (68 år)
Ms. Caroline Jewett VP & Head of Quality 269.26k 1965 (60 år)

Adresse: United States, Westlake Village. CA, 2625 Townsgate Road - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.genelux.com